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Abstract
Botulism is a severe neurological disease caused by the complex family of botulinum neuro-
toxins (BoNT). Based on the different serotypes known today, a classification of serotype
variants termed subtypes has been proposed according to sequence diversity and immuno-
logical properties. However, the relevance of BoNT subtypes is currently not well under-
stood. Here we describe the isolation of a novel Clostridium botulinum strain from a food-
borne botulism outbreak near Chemnitz, Germany. Comparison of its botulinum neurotoxin
gene sequence with published sequences identified it to be a novel subtype within the
BoNT/A serotype designated BoNT/A8. The neurotoxin gene is located within an ha-orfX+
cluster and showed highest homology to BoNT/A1, A2, A5, and A6. Unexpectedly, we
found an arginine insertion located in the HC domain of the heavy chain, which is unique
compared to all other BoNT/A subtypes known so far. Functional characterization revealed
that the binding characteristics to its main neuronal protein receptor SV2C seemed unaffect-
ed, whereas binding to membrane-incorporated gangliosides was reduced in comparison to
BoNT/A1. Moreover, we found significantly lower enzymatic activity of the natural, full-
length neurotoxin and the recombinant light chain of BoNT/A8 compared to BoNT/A1 in dif-
ferent endopeptidase assays. Both reduced ganglioside binding and enzymatic activity may
contribute to the considerably lower biological activity of BoNT/A8 as measured in a mouse
phrenic nerve hemidiaphragm assay. Despite its reduced activity the novel BoNT/A8 sub-
type caused severe botulism in a 63-year-old male. To our knowledge, this is the first de-
scription and a comprehensive characterization of a novel BoNT/A subtype which
combines genetic information on the neurotoxin gene cluster with an in-depth functional
analysis using different technical approaches. Our results show that subtyping of BoNT is
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Introduction
Botulism, a life-threatening disease in humans and animals, is caused by botulinum neurotox-
ins (BoNTs) that are produced by the Gram-positive, anaerobic, spore-forming bacterium
Clostridium (C.) botulinum together with non-toxic associating proteins. To date there are
seven confirmed BoNT serotypes (A–G), and a proposed one (H), of which BoNT/A, B, E, F
and the proposed H are associated with botulism in humans, while BoNT/C and D cause dis-
ease primarily in animals. BoNT/G has not yet been clearly linked to a botulism outbreak in
humans or animals [1–5]. Recently, detailed genetic and proteomic comparisons revealed that
most serotypes can be divided into several subtypes. Smith et al. defined subtypes as two
BoNTs of the same serotype that differ by at least 2.6% in amino acid sequence [6]. However,
BoNT variants showing higher identity have been reported as distinct subtypes for BoNT/B
and E [7,8]. With respect to BoNT/A, five subtypes BoNT/A1 to A5 have been described [7].
Two additional subtypes have been described which fit the above-mentioned definition, but
have not been explicitly designated as new subtypes by the authors [9,10]. Within this paper,
we refer to these molecules as BoNT/A6 and A7, respectively. Altogether, 32 subtypes have
been identified so far for the serotypes relevant to humans (BoNT/A1 to A7, B1 to B8, E1 to
E11, F1 to F7) [6–9,11–17]. For BoNT/C and D no subtypes but mosaic forms have been re-
ported [15,18].
The bont gene is part of a gene cluster that has been shown to exist in two different forms:
ha+orfX-cluster or ha-orfX+ cluster that differ in the composition and arrangement of genes
[1,19]. All but serotype A are associated with a single cluster type. In serotype A the subtypes
bont/a1 and a5 are located within the ha+orfX-cluster; the genes for bont/a1, a2, a3, a4, and a6
are found within the ha-orfX+ cluster. Thus, so far only the bont/a1 subtype exists in
both clusters.
All botulinum neurotoxins are synthesized as single molecules of 150 kDa. Upon activation
by a protease they form dichain toxins composed of a 50 kDa light chain (LC) with zinc-depen-
dent protease activity, linked via a disulfide bond to the 100 kDa heavy chain, comprising a N-
terminal translocation domain (HN) and a C-terminal cell binding domain (HC) [20–22].
After reaching the neuromuscular junction, BoNT first accumulate via binding to complex
polysialo-gangliosides on the surface of motoneurons and subsequently endocytose via interac-
tion with protein receptors into small synaptic vesicles [23,24]. BoNT/A displays a single gan-
glioside binding site in its HC fragment [25,26] and employs the three isoforms of the synaptic
vesicle glycoprotein 2 (SV2A–C) as protein receptor [27,28]. Our analysis shows that the gan-
glioside binding site motif E. . .H. . .SXWY. . .G is conserved throughout BoNT/A1–A8, but
both ganglioside and protein receptor binding of BoNT/A subtypes have not yet been
investigated systematically.
Depending on the serotype, BoNT hydrolyze different neuronal substrate molecules. While
BoNT/A [29,30], C [31] and E [30] cleave synaptosomal-associated protein of 25 kDa (SNAP-
25), BoNT/B [21], D [32], F [33], and G [34] cleave synaptobrevin-2/vesicle-associated mem-
brane protein-2 (VAMP-2) at individual peptide bonds.
Currently the overall relevance of BoNT subtypes is not yet understood. Only few publica-
tions address the characteristics and differences of botulinum neurotoxin subtypes in detail. It
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is known that different subtypes of a given serotype can display different binding characteris-
tics to monoclonal and polyclonal antibodies [6,35–39].
Regarding their functional activity, only little information is available. For the four subtypes
BoNT/A1–A4 Henkel et al. showed that their isolated recombinant LC bind SNAP-25 with
similar affinity but have different turnover frequencies (kcat) for SNAP-25 cleavage [40]. In an-
other study, differential catalytic properties of BoNT/A1 and A5 were described [41]. However,
a recent study showed how different subtypes of a single serotype might behave: it was shown
that the subtype BoNT/F5 cleaves synaptobrevin-2 at a different peptide bond than all other
BoNT/F subtypes, this being the first example of a different substrate cleavage site among sub-
types of a given serotype [42]. While this behavior might well be an exception among the
known subtypes of BoNT serotypes, understanding functional differences is of crucial impor-
tance both for detection technology and for the development of BoNT-based therapeutics
and countermeasures.
With respect to detection, most methods currently employed are based on the detection of
part of the sequence (e.g. PCR, DNA arrays), on the specific binding of antibodies (e.g. ELISA,
immuno PCR) or on the detection of BoNT functional activity (e.g. mouse bioassay, mouse
phrenic nerve hemidiaphragm assay [MPN assay] or endopeptidase assays) or combinations
thereof [43]. Besides identifying novel BoNT subtypes, this implicates that a detailed character-
ization and analysis of subtypes known so far and especially of novel ones is essential to ensure
BoNT detection and to improve BoNT detection methods in order to be able to detect all
BoNT subtypes.
With respect to therapy, the identification and functional characterization of BoNT sub-
types holds the promise of defining improved or alternative therapeutics with modified efficacy
or target spectrum.
The present study describes the isolation, identification and characterization of a novel bot-
ulinum neurotoxin subtype designated BoNT/A8. The novel strain was isolated from green
bean salad causing food-borne botulism in Germany. BoNT/A8 was further characterized by
genomic analysis and mass spectrometric protein sequencing. Additionally, the functional ac-
tivity of the novel BoNT/A8 subtype was comprehensively investigated by addressing the cata-
lytic activity, the receptor binding and the neurotoxicity of the molecule.
Results
Isolation of a BoNT/A8 producing strain
During a food-borne botulism outbreak affecting a 63-year-old male near the city of Chemnitz
in December 2007, suspected food samples (salad of home-canned green beans and two differ-
ent types of sausages) were investigated. The green beans were found positive by multiplex
qPCR for bont/a prior and after anaerobic enrichment culture [44]. Subsequently, the C. botuli-
num strain “Chemnitz” was isolated.
Genomic characterization
Sequencing of the 16S rRNA and bont/a genes of strain Chemnitz confirmed the identity of a
BoNT/A producing C. botulinum group I strain and revealed that the bont/a gene sequence dif-
fered from those published by more than 2.6%, indicating that it might be a novel subtype
(Table 1). The novel bont/a gene showed highest identity to bont/a1, a5 and a6 (96.2–96.6%).
On protein level, the translated sequence differed by at least 6.6% from BoNT/A2 and A5
(Table 1). Most distant from all currently known BoNT/A subtypes was BoNT/A3 with 6.9%
and 12.3% difference on nucleotide and amino acid level, respectively. The novel BoNT/A sub-
type of strain Chemnitz was designated BoNT/A8, the next consecutive subtype number.
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Fig. 1 shows a schematic representation of BoNT/A1 to BoNT/A8, with vertical lines repre-
senting differences in amino acids compared to BoNT/A1. The alignment illustrates that most
differences between BoNT/A1 and BoNT/A8 are located on the heavy chain of the molecule. A
unique feature of BoNT/A8 was a triplet insertion (AGG) at position 2662, leading to an addi-
tional arginine at amino acid position 888. This makes BoNT/A8 the second 1297 aa long
BoNT/A subtype next to the BoNT/A2 of strain CDC2171 [45] (Fig. 1 and S1 Fig.). Overall,
Table 1. Identity of BoNT/A8 to other BoNT/A subtypes on nucleic acid and amino acid levels.*
% pairwise identity
A8 Chemnitz LC HN HCN HCC HC holotoxin
sub-type strain nt aa nt aa nt aa nt aa nt aa nt aa
A1 ATCC3502 97.9 96.8 97.7 95.4 91.0 83.0 97.1 92.6 93.9 87.6 96.5 93.3
A1(B) NCTC2916 97.8 96.3 97.7 95.4 91.0 83.0 97.1 92.6 93.9 87.6 96.5 93.1
A2 Kyoto F 97.8 96.8 93.5 90.0 95.7 92.4 97.6 94.6 96.6 93.4 96.0 93.4
A3 Loch Maree 90.5 82.4 92.7 88.2 95.4 91.9 97.4 93.6 96.3 92.7 93.1 87.7
A4 657Ba 93.8 87.9 93.1 89.4 94.8 88.8 96.6 91.2 95.6 89.9 94.2 89.1
A5 H04402065 98.0 96.3 97.0 94.2 92.7 86.5 96.9 93.1 94.7 89.7 96.6 93.4
A6 CDC41370 97.8 96.6 97.2 95.1 92.5 85.7 94.8 88.7 93.6 87.1 96.2 93.0
A7 2008–148 97.5 95.0 94.4 89.4 93.0 87.0 96.1 92.2 94.5 89.5 95.5 91.3
E3 Alaska E43 49.5 32.7 57.4 36.9 70.8 52.4 56.6 37.1 64.0 45.1 56.9 38.1
F1 Langeland 52.3 32.7 56.6 36.9 72.6 54.9 59.6 42.2 66.4 48.8 58.4 39.4
* Shown is the percentage of nucleic acid (nt) and amino acid (aa) identity among the subtypes BoNT/A1 to A8 subdivided into light chain (LC), N-terminal
domain (HN) and C-terminal domain (HC) of the heavy chain (HC) and of the holotoxin. Additionally, the N-terminal (HCN) and C-terminal (HCC)
subdomains of HC are displayed. Highest percentage of identity (±0.5) is depicted in bold and lowest percentage of identity (±0.5) is depicted in italic.
doi:10.1371/journal.pone.0116381.t001
Fig 1. Comparison of BoNT/A subtypes. BoNT/A1 amino acid sequence of strain ATCC 3502 as prototype was compared to representatives of subtypes
BoNT/A2 to A7 and the novel BoNT/A8. Sequence differences are indicated by vertical lines. The cartoon indicates the domain of the light chain (LC), theN-
terminal part (HN) and theC-terminal part (HC) of the heavy chain (HC). The latter can be further subdivided into an N-terminal (HCN) andC-terminal (HCC)
subdomain. The alignment illustrates that the majority of differences between BoNT/A8 and A1 are located in the heavy chain. Furthermore, the arginine
insertion at position 888 is unique to BoNT/A8.
doi:10.1371/journal.pone.0116381.g001
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BoNT/A8 showed 87 amino acid mutations compared to BoNT/A1, with 12 amino acid substi-
tutions at positions being unique for BoNT/A8 (Fig. 2A and S1 Fig.).
We compared the identities of the four domains and subdomains of BoNT/A8 to other
BoNT/A subtypes and also to BoNT/E and BoNT/F as closest relatives (Table 1). The identities
for the domains and subdomains vary greatly. E.g. whereas the holotoxin and LC of BoNT/A8
had the lowest identity towards BoNT/A3 (Loch Maree), the identity of the HCN subdomain
between BoNT/A8 and BoNT/A3 was one of the highest. Conversely, BoNT/A1 showed the
highest identity to BoNT/A8 for the LC and HN domains whereas the HCN subdomain differed
the most.
Fig 2. Surface representation of BoNT/A8 and arginine insertion. (A) Surface representation of BoNT/A
(PDB code 3BTA [96]). Differences of BoNT/A8 to BoNT/A1 are marked in yellow, unique amino acid
differences in BoNT/A8 (based on the representatives of BoNT/A2 to A7 used in Fig. 1) are marked in red,
and the arginine insertion in position 888 is marked in green. (B) Representative MS/MS spectra of the
precursor ion m/z 923.01 ([M+2H]2+], inset) of BoNT/A8 with the sequence of 872NITNTSILSIVVDKDGR888,
showing the additional arginine at position 888 leading to an additional trypsin cleavage site.
doi:10.1371/journal.pone.0116381.g002
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BoNT/A is the only serotype encoded either in an ha+orfX-or an ha-orfX+ neurotoxin gene
cluster. To elucidate the organization of the neurotoxin gene cluster of strain Chemnitz, we ap-
plied whole genome shotgun sequencing (454 sequencing on a GS FLX+ System, Roche). Addi-
tionally, the gene cluster was partly verified by Sanger sequencing and is available under
GenBank accession number KM233166. Noteworthy, Sanger sequencing of the bont/a gene
with the primers published by Hill et al. [7] resulted in a different last amino acid as compared
to the 454 shot gun sequence (L!Q). This is based on the fact that the Sanger sequence was
forced by the primer 6R sequence to CTG (encoding L) instead of the CAG (encoding Q)
which was unambiguously obtained by whole genome sequencing. The bont/a8 cluster be-
longed to the ha-orfX+ type (Fig. 3) which is known to encode BoNT/A1, A1(B), A2, A3, A4,
and A6 subtypes as well as BoNT/E and F serotypes [15]. The bont/a8 gene cluster was located
within the ars operon on the chromosome like other ha-orfX+ BoNT/A- and BoNT/F-produc-
ing strains of group I and is flanked by the arsC and the lycA genes [46]. Noteworthy, the
whole bont/a8 gene cluster—with the exception of the bont/a8 gene itself—was closest related
to the bont/f1 gene cluster of strain Langeland also belonging to C. botulinum group I (Fig. 3,
Table 2 and Table 3).
Protein sequencing of BoNT/A8
In addition to genomic characterization, the protein sequence of BoNT/A8 was analyzed by
high resolution LC-MS/MS. After immunoaffinity enrichment the BoNT was digested with
three endopeptidases (AspN, trypsin and chymotrypsin), leading to a sequence coverage of
~67%. MS/MS spectra of the doubly charged precursor ion m/z 923.01 revealed the amino acid
sequence 872NITNTSILSIVVDKDGR888 and verified the arginine insertion at position 888
(Fig. 2B), which led to an additional trypsin cleavage site. Additionally, 57 out of 87 amino acid
mutations deduced from nucleotide sequence could be confirmed by this protein sequencing
approach (S2 Fig.).
Fig 3. Bont/a8 gene cluster organization. Schematic representation of the neurotoxin gene clusters from the prototype BoNT/A1 strain ATCC 3502, BoNT/
A1(B) strain NCTC 2916, BoNT/A8 strain Chemnitz, and BoNT/F1 strain Langeland. The bont/a1 gene from ATCC 3502 is located within an ha+orfX-cluster
containing the non-toxic non-haemagglutinin (ntnha) gene, the three haemagglutinin genes (ha70, ha17 and ha33) and the regulatory botR gene. The bont/
a1 neurotoxin gene cluster of ATCC 3502 is flanked by the flagellin (fla) gene and an insertion sequence element (IS). In contrast to the prototype bont/a1
(ATCC 3502), the bont/a1 of NCTC 2916 and the bont/a8 gene of Chemnitz are located in an ha-orfX+ cluster which contains the adjacent ntnha gene and—
instead of the ha genes—the three orfX1–3 genes; apart from the botR gene the cluster also contains the p47 gene of unknown function. The neurotoxin
gene clusters of NCTC 2916 and Chemnitz are located within the ars operon on the chromosome and are flanked by the arsC and the lycA genes. Except for
the toxin gene itself, its gene cluster organization and sequence is most similar to the bont/f1 gene cluster of strain Langeland.
doi:10.1371/journal.pone.0116381.g003
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Furthermore, the MS/MS data of the novel subtype were used to challenge the amino acid
substitution database recently described [13]. The amino acid substitution database identified
nine of the 12 unique point mutations in BoNT/A8 compared to the sequence of BoNT/A1
and the other known subtypes (S1 and S2 Figs.). On this basis the substitution database classi-
fied BoNT/A8 as “novel” subtype.
Recognition by antibodies
We tested whether the observed differences on protein level resulted in an altered antibody rec-
ognition pattern: both BoNT/A8 and BoNT/A1 were recombinantly expressed as single-chain
molecules, immobilized on a 96-well plate and tested for binding a panel of monoclonal and
polyclonal antibodies generated in-house ([47–49] and unpublished data). As shown in Fig. 4,
a number of monoclonal antibodies (mAbs) showed no difference in recognizing BoNT/A1
and A8, while others showed a reduced binding or even a complete loss of binding to BoNT/
A8 (mAb HcA16/6, HcA78/6, HcA86/2, A324/10, and A401/3).
The antibodies showing a differential binding between BoNT/A1 and BoNT/A8 recognize
different epitopes on the BoNT molecule, with mAb HcA16/6, HcA78/6 and HcA86/2 being
directed against the HC-domain, mAb A401/3 recognizing the LC domain and mAb A324/10
recognizing a yet to be determined conformational epitope on the molecule. Binding to two
polyclonal antibodies raised in rabbit (AR47) or chicken (AC29) was not affected (Fig. 4).
Receptor binding of BoNT/A8
Little is known about the functional consequences of the sequence differences of BoNT sub-
types. Most of our knowledge regarding binding of BoNT to the synaptic membrane, transcyto-
sis and proteolytic action towards SNAP-25 is based on the archetype BoNT/A1. In our first
set of experiments we investigated if differences in the amino acid sequence affect binding to
the synaptic cell surface. Binding of BoNT/A follows a two-receptor model in which BoNT/A
shows a low affinity interaction towards gangliosides and a high affinity binding to synaptic
Table 2. Sequence identity of individual genes within the neurotoxin gene cluster of strain Chemnitz encoding BoNT/A8 compared to other
BoNT/A, E and F sero- and subtypes located in an ha-orfx+ gene cluster on nucleotide levels.*
Subtype Strain bont ntnha p47 botR orfX1 orfX2 orfX3
A1 ATCC 3502 96.5 86.5 n/a 75.6 n/a n/a n/a
A1(B) NCTC 2916 96.5 94.9 99.5 94.9 93.2 97.9 96.1
A2 Kyoto F 96.0 97.2 86,3 96.4 95.6 98.2 96.8
A3 Loch Maree 93.1 96.0 87.4 97.7 95.1 97.2 94.2
A4 657 94.2 96.5 81.9 98.3 91.9 86.8 95.6
A5 H04402 065 96.6 86.5 n/a 76.0 n/a n/a n/a
A6 CDC41370 96.2 97.4 87.4 89.8 93.2 98.0 95.6
A7 2008–148 95.5
E3 Alaska E43 56.9 85.6 85.2 n/a 79.3 66.0 82.3
F1 Langeland 58.4 98.3 99.8 100.0 99.8 99.9 99.9
* The neurotoxin gene clusters encoding for BoNT, NTNHA, p47, BotR and the OrfX1, OrfX2 and OrfX3 proteins were compared between strain Chemnitz
(BoNT/A8) and the other BoNT/A subtypes (A1 to A7) and percent identities are given either on nucleic acid level (A) or on amino acid level (B). For
comparison the identities to BoNT/E and BoNT/F also located within an ha-orfX+ neurotoxin gene cluster are displayed, too. Highest identities (±0.5) are
depicted in bold and lowest identities (±0.5) are depicted in italic. Empty cells indicate that no sequence data exist while n/a denotes the absence of
certain genes from the neurotoxin gene cluster.
doi:10.1371/journal.pone.0116381.t002
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vesicle glycoprotein 2 (SV2) family members [23]. BoNT/A1 displays the highest affinity to the
luminal domain 4 of SV2 isoform C [27]. First we analyzed binding of the recombinant isolated
cell binding domain HC to its immobilized protein receptor rat SV2C. The corresponding 126
aa peptide 454–579 has been fused to glutathione-S-transferase (GST) to allow immobilization
on GT-matrix [27]. GST-rSV2C 454–579 could equally well precipitate HCA1 and HCA8 from
Table 3. Sequence identity of individual genes within the neurotoxin gene cluster of strain Chemnitz encoding BoNT/A8 compared to other
BoNT/A, E and F sero- and subtypes located in an ha-orfx+ gene cluster on amino acid levels.*
Subtype Strain BoNT NTNHA p47 BotR OrfX1 OrfX2 OrfX3
A1 ATCC 3502 93.3 76.7 n/a 61.2 n/a n/a n/a
A1(B) NCTC 2916 93.1 92.4 99.3 91.0 89.4 97.7 95.1
A2 Kyoto F 93.4 95.5 79.1 92.1 93.0 97.1 95.7
A3 Loch Maree 87.7 94.6 79.6 95.5 93.0 95.7 93.5
A4 657 89.1 94.1 73.8 97.2 87.3 78.2 94.3
A5 H04402 065 93.4 76.7 n/a 62.9 n/a n/a n/a
A6 CDC41370 93.0 95.9 79.8 79.8 89.4 97.6 94.5
A7 2008–148 91.3
E3 Alaska E43 38.1 76.0 81.0 n/a 73.9 51.3 76.7
F1 Langeland 39.4 96.2 100.0 100.0 99.3 99.7 99.6
* The neurotoxin gene clusters encoding for BoNT, NTNHA, p47, BotR and the OrfX1, OrfX2 and OrfX3 proteins were compared between strain Chemnitz
(BoNT/A8) and the other BoNT/A subtypes (A1 to A7) and percent identities are given either on nucleic acid level (A) or on amino acid level (B). For
comparison the identities to BoNT/E and BoNT/F also located within an ha-orfX+ neurotoxin gene cluster are displayed, too. Highest identities (±0.5) are
depicted in bold and lowest identities (±0.5) are depicted in italic. Empty cells indicate that no sequence data exist while n/a denotes the absence of
certain genes from the neurotoxin gene cluster.
doi:10.1371/journal.pone.0116381.t003
Fig 4. Differential binding of antibodies to BoNT/A1 and BoNT/A8.Native or recombinantly expressed single chain BoNT/A1 and single chain BoNT/A8
were coated onto microtiter plates and tested in an indirect ELISA for capturing a panel of monoclonal and polyclonal antibodies generated in-house. All
antibodies shown are monoclonal antibodies except for AR47 and AC29 which are polyclonal antibodies derived from rabbit and chicken, respectively.
Shown is the mean (± SD) of three independent experiments performed in duplicates.
doi:10.1371/journal.pone.0116381.g004
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the supernatant, indicating no change in affinity towards their protein receptor (Figs. 5A and
5B). We then measured the interaction with gangliosides by the interaction of the HC-domain
with synaptosomes at 4°C. In contrast to an equal interaction with the protein receptor, the
binding of radiolabeled 35S-HCA1 to synaptosomes was inhibited by lower concentrations of
recombinant HCA1 than those of HCA8. Whereas recombinant HCA1 displayed an EC50 of
24 nM (95% CI 20–29 nM), 2.5-fold more HCA8 was required to displace
35S-HCA1
(EC50 = 56 nM, 95% CI 43–72 nM), indicating that HCA8 has a lower binding affinity to gan-
gliosides incorporated in neuronal membranes compared to HCA1 (Fig. 5C).
Enzymatic activity of BoNT/A8
After characterization of the binding domain we explored the LC for differences in its catalytic
activity. In order to analyze the endopeptidase activity of BoNT/A8 in comparison to BoNT/
A1, a combination of immunoaffinity enrichment plus mass spectrometric quantification of
substrate cleavage was performed [50]. The native toxins were enriched from cell-free culture
Fig 5. Binding characteristics of BoNT/A8 cell-binding domain HC. (A) Binding affinity of HCA8 to its synaptic protein receptor rat SV2C in a GST pull-
down assay is similar to HCA1. 12.5% SDS-PAGE and Coomassie staining of a representative pull-down experiment. (B) Densitometric quantification of
bound HC-fragments from (A) (n = 4 ± SD). (C) Competition assay: Binding of
35S-HCA1 to synaptosomes at 4°C in the presence of increasing amounts of
recombinant HCA1 or HCA8, respectively. Bound
35S-HCA1 was detected by SDS-PAGE and autoradiography (n = 3 ± SD; HCA1: EC50 = 24 nM (95%CI 20–
29 nM), HCA8: EC50 = 56 nM, 95% CI 43–72 nM)).
doi:10.1371/journal.pone.0116381.g005
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supernatants using mAb 4E17.1 coupled to magnetic beads which recognizes the strictly con-
served epitope YNQYTEEEK (aa 751–759; [51] and S1 Fig.). Captured toxins were then incu-
bated in an Endopep-MS assay with a cleavable 22-mer SNAP-25 peptide. We found that
BoNT/A8 showed only about 28% activity compared to that of BoNT/A1 (Fig. 6A). It has been
described that the antibody used for immunocapturing the BoNT might affect the catalytic ac-
tivity of LC in a subtype-dependent manner [38,39]. To exclude any deleterious effects of the
antibody used, we omitted the immunocapture step and compared the activity of recombi-
nantly expressed LC only. LC of BoNT/A1 and BoNT/A8 were incubated with the full-length
human SNAP-25 protein, and catalytic activity was determined in an Endopep-MS assay. Con-
sistent with the results obtained with the native full-length molecule we found a dramatic re-
duction in catalytic activity to about 10% when comparing the activity of LC/A8 to that of
LC/A1 (Fig. 6B).
Moreover, the findings of the Endopep-MS assay could be confirmed in an independent ex-
perimental setting measuring rat SNAP-25 wild-type cleavage in a time-dependent endopepti-
dase assay, where the cleavage activity was determined by SDS-PAGE and densitometric
quantification of the cleavage product. Again, results clearly corroborated the fact that LC/A8
displays a lower rate of catalysis than LC/A1 (Fig. 6C).
Biological activity of BoNT/A8
To verify whether the altered characteristics in binding and catalytic activity results in a modi-
fied biological activity, the potency of full-length BoNT/A1 and BoNT/A8 molecules—recom-
binantly expressed as single-chain molecules and activated in vitro—was determined
employing the MPN assay which represents the physiological site of action of BoNT. Compari-
son of the three-point dose—response curves (Fig. 7) yielded an about six-fold reduced biologi-
cal activity of BoNT/A8 versus BoNT/A1, caused by the reduced binding and catalytic
properties of BoNT/A8.
Discussion
Here we describe the isolation and characterization of a novel C. botulinum strain from a food-
borne botulism case near Chemnitz, Germany. Comparison of its BoNT/A sequence to the pre-
viously published sequences reveals that it constitutes a novel subtype, designated as the next
consecutive number BoNT/A8.
The comparison of the BoNT/A sequences of strain CDC41370 [9] and strain 2008–128
[10] showed at least 2.6% difference on amino acid level to the previously described subtypes
A1 to A5 [7,52,53]. Although the differences for both sequences were noted by the authors, no
novel subtypes were assigned in their original publications [9,10]. For the sake of consistency
we decided to designate these two BoNT/A sequences as subtypes BoNT/A6 (CDC41370) and
BoNT/A7 (2008–128), respectively, in this work. BoNT/A8 displays the highest homology
(~93.3%) to BoNT/A1, A2 and A5. Interestingly, BoNT/A2 is encoded in an ha-orfX+ gene
cluster like BoNT/A8 which yields only the 300 kDa M-progenitor toxin complex (M-PTC)
comprising BoNT/A and the non-toxic non-haemagglutinin (NTNHA) [54]. Recently, it has
been demonstrated that only the fully functional 760 kDa large PTC (L-PTC) comprising the
additional dodecameric haemagglutinin (HA) complex displays high oral toxicity [55]. Never-
theless, strain Chemnitz producing BoNT/A8 caused a serious case of food-borne botulism
which poses the question whether the three OrfX proteins or other unknown clostridial pro-
teins can adopt the function of the HA complex to achieve high oral toxicity.
Comparison of the protein sequences of BoNT/A8 with BoNT/A1 showed that BoNT/A8
includes an insertion of a single Arg at position 888, rendering A8 with 1297 aa the longest of
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Fig 6. Comparison of the catalytic activity of BoNT/A1 and BoNT/A8. (A) Quantitative mass
spectrometric endopeptidase assay of native full-length BoNT/A1 and BoNT/A8 immunoenriched from cell
culture supernatants tested for cleavage of a SNAP-25 peptide substrate. (B) Quantitative mass
spectrometric endopeptidase assay of recombinant light chains of BoNT/A1 and BoNT/A8 tested for
cleavage of human H6SNAP-25 protein. Both diagrams show the percentage of BoNT/A8 substrate cleavage
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all known BoNT/A subtypes. Noteworthy is also the change of the final amino acid from leu-
cine to glutamine which could only be identified by 454 shotgun data analysis; initially, the
primer BoNT A-6R described by Hill et al. [7] changed the terminal DNA triplet to a codon en-
coding leucine, as present in A1 to A7.
Interestingly, one other published C. botulinum strain, CDC2171 of subtype A2 (GenBank:
GQ241939) [45], also consists of 1297 aa and comprises a glutamic acid residue inserted at po-
sition 888 and glutamine at position 1297. Noteworthy, this particular strain showed the high-
est overall identity of 94.3% towards strain Chemnitz. A detailed comparison on the level of
subdomains of CDC2171 with strain Chemnitz revealed that in particular the HCN and HCC
domains were highly identical (95.1% and 98.0% identity, respectively) while the HN domain
showed a lower identity of 89.6% and the identity of the LC (96.8%) was close to subtypes
BoNT/A1, A5, A6, and A7.
While the BoNT/A8 itself showed highest identity with BoNT/A subtypes, we intriguingly
found the highest identity of the other genes in the neurotoxin gene cluster, namely ntnha,
orfX1–3, BotR and p47, with that of strain Langeland encoding BoNT/F1. However, the indi-
vidual subdomains of BoNT/A8 are not highly related to BoNT/F1. This finding allows the in-
terpretation that BoNT/A8 is localized in a BoNT/F1 gene cluster.
It has been recognized before that BoNT/A and F producing bivalent strains exist [12,56],
even a trivalent BoNT/A2, F4 and F5 producing strain has been identified [57–59]. Notably, re-
cent analysis of the proposed novel serotype H indicated that this BoNT could also be described
as F5A1 mosaic form [60,61]. Indeed, when we compared the HCC domain of BoNT/A8 with
the one of the proposed BoNT/H (GenBank: KGO15617) we found 95.1% identity on amino
acid level whereas the identities for the other domains were significantly lower (LC: 31.2%, HN:
39.0%, HCN: 67.1%). On the basis of these findings one could speculate that recombination
compared to BoNT/A1 (n = 3 ± SD). (C) Time-dependent cleavage of rat SNAP-25H6 (3 μM) by LC/A1 and
LC/A8 (0.5 nM). The amount of cleavage product was quantified densitometrically from SDS-PAGE stained
by Coomassie (n = 3 ± SD).
doi:10.1371/journal.pone.0116381.g006
Fig 7. Biological activity of BoNT/A1 and A8. The biological activity of recombinant full-length active BoNT/
A1 and BoNT/A8 was determined employing the mouse phrenic nerve hemidiaphragm (MPN) assay. To a
three-point dose—response curve (n 3 ± SD) of each subtype a power function was fitted. To yield an
identical paralytic halftime, six-fold higher concentrations of BoNT/A8 are required.
doi:10.1371/journal.pone.0116381.g007
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events or interchange of bont or other toxin cluster genes occurs more likely between serotypes
A and F and that the neurotoxin gene cluster of strain Chemnitz might be the result of a trans-
fer of bont/a8 into the bont/f1 gene cluster. This can only be corroborated by a detailed com-
parison of the backbone of strain Chemnitz versus strain Langeland in the future.
It is an ongoing debate among the BoNT community what differences qualify a toxin gene
to be called a novel, distinguishable subtype. Different definitions have been proposed, e.g. dif-
ferential recognition and neutralization by antibodies, different primary sequence—with the
inherent question of where to set the threshold between different subtypes—or different func-
tional aspects of individual toxin variants/subtypes. The current definition of subtypes based
on differences on amino acid level of at least 2.6% [6] is to a certain degree arbitrary. Also, de-
pending on the serotype, different thresholds have been set; e.g. the subtypes E1 to E3 differ
only between 1 to 3% [7]. Historically, the typing of BoNTs is nearly as old as its discovery.
Soon after van Ermengen had isolated and described the first strain [62], it was noted that the
toxic supernatant of this strain differed from that of another strain isolated from bean salad in
Darmstadt [63] not only biochemically but also antigenically, as the corresponding antitoxins
did not cross-neutralize each other [64]. Thus the first two serotypes were born. However, the
very recent issue of subtyping of serotypes is more difficult, since we and others noted a large
variability among the sequences of specific BoNT serotypes, including amino acid variations
within a given subtype [6,7,13]. Generally, a few point mutations at critical positions might in-
terfere with recognition of antibodies or modify functional characteristics, even if the distance
to other subtypes is less than 2.6%. So in one extreme, if each different sequence would be des-
ignated as individual subtype, we might end up with countless BoNT subtypes. On the other
hand, no subtyping would lead to a confusing situation and would severely impede comparison
of different study results.
There is no question that differences in the sequence might significantly affect detection ei-
ther on DNA or protein level, and in fact this has been recognized for some subtypes in the
past [6,36,38,65] and can also be demonstrated for BoNT/A8 versus BoNT/A1 with a panel of
different antibodies. However, one of the most intriguing questions is whether the observed se-
quence variation in BoNT/A8 does affect the biological activity. The overall functional activity
of BoNT comprises the catalytic activity of the LC domain, the cell-binding activity of the HC
domain and the translocation activity of the HN domain. Some predictions can be made based
on the amino acids identified to be essential for the process (e.g. catalysis, substrate or receptor
binding). The limitation of such a theoretical approach lies in the unpredictability of the com-
plex three-dimensional interactions within the protein structure and a lack of knowledge of all
atomic interactions during pathogenesis. So far, there is little experimental data on functional
activity of known subtypes. Henkel et al. compared the catalytic activity of the isolated LC
from BoNT/A1, A2, A3 and A4. While LC/A1 and LC/A2 were found to have similar activity
towards GST-SNAP-25 (aa 141–206), LC/A3 was 2-fold and LC/A4 23-fold less active [40].
However, others found substantial time-dependent differences in the cleavage efficacies be-
tween subtypes BoNT/A1 to A5. [66]. Additionally, Wang et al. identified different cleavage ki-
netics for BoNT/A1 and A5 [41].
When we compared the catalytic activity of either the native full-length BoNT/A8 from cul-
ture supernatants or the isolated recombinant LC from BoNT/A8 with the respective molecule
of BoNT/A1, we found its activity towards full-length hSNAP-25 or a SNAP-25-derived pep-
tide significantly reduced to about 10–28% of the activity of BoNT/A1 in Endopep-MS assays
(Fig. 6A and B). In a different approach with full-length rat SNAP-25, a different buffer system
and a different read-out the LC/A8 activity also displayed reduced activity compared to LC/A1
but only by 10–20% (Fig. 6C). While the rat and human SNAP-25 amino acid sequences are
identical, the buffer system and assay time have been found to influence the LC activity greatly
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[66–68]. Indeed, for the Endopep-MS assay (Fig. 6A and B) a buffer consisting of 20 mM
HEPES pH 7.3, 10mM dithiothreitol, 20 μMZnCl2 and 1 mg/mL BSA [50] was used, whereas
150 mM potassium glutamate and 20 mMHEPES-KOH, pH 7.2 [69] was used for the time-
dependent endopeptidase assay (Fig. 6C). In fact, dithiothreitol, ZnCl2 and BSA have been
shown to have a major impact on the catalytic activity [67,68]. So the differences observed in
Fig. 6A/B versus Fig. 6C with respect to catalytic activity might well reflect the different reac-
tion conditions used to compare BoNT/A8 and BoNT/A1. Importantly, irrespective of the in-
dividual assay conditions used to compare both molecules in different endopeptidase assay
formats, we always observed a reduced activity of BoNT/A8, underlining the validity of the re-
sults in different in vitro functional assays. In BoNT/A8, 12 amino acid residues within the 438
amino acids of LC are substituted compared to BoNT/A1. Only four of those residues (T13,
I17, K55 and N270) also differ from LC/A2 (S1 Fig.) which is nearly as catalytically active as
LC/A1 [40]. Superimposition of a structural model based on the amino acid sequence of LC/
A8 1–438 on the co-crystal structure of LC/A1 and SNAP-25 [70] as well as a LC/A2 as mono-
mer [71] revealed only few substituted residues in the vicinity of the substrate-binding cleft. In-
terestingly, Arg191 of SNAP-25 which follows just after the SNAP-25 loop 187–189 and is in
close proximity to the scissile peptide bond (Gln197-Arg198) is coordinated by E171 in LC/A1.
In LC/A8 an aspartate is found at position 171, which could lead to an impaired salt bridge for-
mation; however, LC/A2 also comprises D171. Furthermore, on the opposite rim of E171 the
residue E55 is exclusively replaced by a lysine in LC/A8. Such a charge reversal was expected to
repel Arg191 of SNAP-25 and thereby weaken the substrate binding of SNAP-25 to LC/A.
However, substituting E55 in LC/A1 for lysine did not impair time-dependent substrate cleav-
age of SNAP-25 (aa 1–206). Accordingly, the mutant LC/A8 K55E neither showed an increased
cleavage rate compared to LC/A8 wild type nor reached the activity of LC/A1 wild type (Bache-
lor thesis Alexander Bollenbach [72]).
While the catalytic activity is one major factor of the toxin’s biological toxicity, receptor
binding contributes as well and was therefore analyzed in detail for BoNT/A8 versus BoNT/
A1. For high affinity binding to the synaptosomal cell membrane two different binding events,
namely binding to a ganglioside and the synaptic vesicle glycoprotein 2 (SV2), have been iden-
tified [23]. It has been shown that isoform SV2C is most crucial for uptake of the BoNT mole-
cule [27]. The binding of the HC-fragments of BoNT/A1 and A8 to SV2C was comparable in
an in vitro pull down assay (Fig. 5). This is in accordance with amino acids identified in the co-
crystal structure being critical for the interaction of BoNT/A1 with human SV2C, namely
T1145, T1146 and Y1149 [73], which are conserved between BoNT/A1 and BoNT/A8 (T1146,
T1147 and Y1150 due to R888 insertion). However, R1156 thought to interact with F563 of
human SV2C is found exclusively in BoNT/A1 and only BoNT/A2 comprises E1156 whereas
all other known subtypes including BoNT/A8 display a methionine at position 1156/7 which
still permits interaction with hydrophobic residues such as F563. R1294/5 contributing to the
positive surface charge [73] is converted to serine in BoNT/A2, A3, A5, A7, and A8 but to ly-
sine in BoNT/A6. Thus, none of the other BoNT/A subtypes contains R1156 and R1294. We
found that in accordance with this loss of surface charge in the SV2 binding site, BoNT/A8
showed reduced salt-dependency in the interaction with rat SV2C as measured by surface plas-
mon resonance (Daniel Stern, Robert Koch-Institut). In a more recent publication Strotmeier
and colleagues identified further residues important for the interaction with SV2C [74]. Three
of the identified positions whose mutation alters SV2C binding of BoNT/A1 (N905Y, T1063P,
H1064G) divert in BoNT/A8 (N906S, T1064P, H1065R). The exchange N906S introduces a
less bulky side chain than the tested N905Y and as such may be of little importance. The ho-
mologous substitution of the basic histidine at 1065 by the basic arginine might also not influ-
ence SV2C binding. However, T1063P greatly reduces binding of BoNT/A1 to rat SV2C in the
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pull-down assay, but no such reduction was seen for BoNT/A8 in a very similar experimental
setting, which might be due to a compensation by other residue exchanges.
While we did not observe differences in SV2C binding experimentally, we found the interac-
tion of HCA8 with gangliosides in neuronal membranes markedly reduced. The single ganglio-
side-binding site (GBS) of BoNT/A is formed by 12 residues and contains the conserved GBS
motif E. . .H. . .SXWY. . .G [23]. All six residues are identical in BoNT/A1 and BoNT/A8. Only
L1278, a less important contact point, is replaced by F1279 in BoNT/A8 which introduces an
aromatic functionality but still maintains the hydrophobic character of this part of the ganglio-
side-binding pocket. However, the binding to synaptosomes at 4°C which is predominantly
mediated via interaction with gangliosides is clearly reduced for BoNT/A8, which cannot be ex-
plained by the L1279F exchange. In the neighborhood of the GBS the surface-exposed loop
1271–1274 (IERS) is mutated to V1272GKA1275 in BoNT/A8. Due to the short carbohydrate
chain of gangliosides, the GBS-surrounding surface will be in close proximity of the membrane
surface, and a negative influence of the altered loop 1272–1275 seems reasonable. Furthermore,
whereas in the HCC-domain 15 of the 205 residues are substituted in BoNT/A8, the HCN even
displays 38 exchanges including the insertion of R888. A role of the HCN domain in phospho-
lipid binding has been suggested, although no individual residues could be identified [75].
Hence it is possible that the larger differences in the HCN domain also contribute to the clearly
decreased binding of HCA8 to neuronal membranes. In the above-mentioned recent study of
Strotmeier et al. [74] some residues of importance for BoNT/A1 toxicity are described. E.g.
Q915R showed little effect on SV2C binding but a 50% reduced toxicity. In BoNT/A8 the Q915
is replaced by lysine, which also introduces a positive charge. Although speculative, this ex-
change might compromise the interaction with the cell surface or simply hinder certain confor-
mational changes occurring during binding and/or translocation.
When comparing two proteins differing by one amino acid only, a potential assignment in
functional consequences is straightforward. In our situation, however, where a number of resi-
dues differ simultaneously, interpretation is rather difficult. Individual effects caused by one
amino acid exchange might be reversed by another one; also previously unrecognized residues
might have an important impact on protein—protein interaction when replaced by another
amino acid. Thus, deduction of the functional activity of a protein based on amino acid se-
quence alone can be misleading and needs experimental investigation.
Due to the complex interplay of cell binding, uptake, transcytosis and catalytic activity, pre-
dictions on the overall toxicity based on the activity of single domains can be inaccurate.
Whereas Henkel et al. found the catalytic activities of the LC from A1 and A2 comparable, oth-
ers described more profound differences of the full-length molecules in cell culture [66,76,77]
or in vivo [78,79]. To test whether the observed differences in catalytic activity and ganglioside
binding affects the overall toxicity of BoNT/A8, both the novel subtype and BoNT/A1 were ex-
pressed as full-length proteins in E. coli and tested in an MPN assay which measures the neuro-
toxicity in an ex vivo approach. Indeed, BoNT/A8 turned out to have a profound reduction in
biological activity (about 6-fold) as compared to BoNT/A1, thus extending the differences ob-
served between single domains onto the full-length molecule.
In summary, we describe and characterize the novel subtype BoNT/A8 that was associated
with a case of food-borne botulism in Germany. To our knowledge, this is the first comprehen-
sive description of a novel BoNT subtype providing information both on the genomic organi-
zation of the neurotoxin gene cluster and information on the functional characteristics of the
toxin’s domains based on different technical approaches. Finally, even though the toxin pro-
duced a severe case of food-borne botulism in the patient, the determination of the overall tox-
icity of the novel subtype demonstrated a significant reduction in neurotoxicity as compared to
BoNT/A1. Independent of the definition criteria of a novel subtype, our BoNT/A8 has to be
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designated as new subtype since it can be distinguished from other BoNT/A subtypes based on
(i) sequence variation larger than 2.6%, (ii) different antibody recognition pattern as well as
(iii) altered functional/biological activity.
Our results show that subtyping of BoNT is highly relevant and necessary to effectively fight
the very sophisticated BoNT molecule. While a reduction in biological activity as identified in
this novel subtype does not cause concern under the aspect of biosecurity, the opposite might
well be found in a yet unknown subtype. On the other hand, identification and in-depth char-
acterization of BoNT/A subtypes might pave the way for developing novel therapeutics for dif-




This study does not comprise animal experiments according to the German Protection of Ani-
mals Act (TierSchG dated 13.07.2013) and European Union Directive 2010/63/EU for the pro-
tection of animals used for experimental purposes. NMRI mice for the MPN assay were
obtained from Janvier SAS (St. Berthevin Cedex, France). According to §4.3 (killing of animals
for scientific purposes, TierSchG) animals were anesthetized with carbon dioxide and sacrificed
by trained personnel before dissection of organs. All efforts were made to minimize suffering.
This project no. §4.3/19 was approved by the animal welfare officer of the Central Animal Labo-
ratory of the Medizinische Hochschule Hannover. Consumption of animals was reported yearly
to the animal welfare officer and to the local authority, Veterinäramt Hannover, Germany.
Bacterial strains
Strains used in the present study were NCTC 7272 (ATCC 19397) expressing BoNT/A1 and
strain Chemnitz expressing BoNT/A8 (own isolate, Robert Koch-Institut; [44]). Clostridia
strains were cultured in tryptone-peptone-glucose-yeast extract (TPGY) broth for up to 4 days
at 32°C in an anaerobic workstation (MACS 500, DonWhitley Scientific, West Yorkshire,
United Kingdom). Cell-free supernatants were obtained from clostridial cultures after centrifu-
gation (12,000 × g, 5 min, 4°C) and filtration through a 0.2 μm filter.
For sequence comparison the following Genbank entries were used throughout this work:
Subtype A1, strain “Hall 174” (ATCC 3502) GenID NC_009495.1 [80,81]; subtype A1(B),
“Hall 2447” (NCTC 2916) X52066, AY497357, NZ_ABDO02000001 [81–83]; subtype A2,
“Kyoto-F”, NC_012563.1 [84]; subtype A3, “Loch Maree”, NC_010520.1 [85,86]; subtype A4,
“657Ba”, NC_012658 [86]; subtype A5, “H04402 065”, NC_017299 [87,88]; subtype A6,
“CDC41370”, FJ981696 [9]; subtype A7, “2008–148”, JQ954969 [10]; subtype E3, “Alaska
E43”, NC_010723 [89]; and subtype F1, “Langeland”, NC_009699 [90].
DNA isolation and sequencing
DNA from TPGY cultures was extracted with the DNeasy Blood and Tissue Kit (Qiagen, Hil-
den, Germany) according to the manufacturer’s protocol for Gram-positive bacteria.
Sanger Sequencing of 16S rDNA and bont/a genes was performed as described [7]. For BoNT/
A8 an alternative A-1F primer sequence CGGTAAATATATATGTTTATCTAT was used.
For whole genome sequencing the 454 FLX Titanium kit (Roche, Branford, CT) was used
on a GS FLX+ System (Roche) after quality assessment of the extracted DNA with the Quant-
iT PicoGreen dsDNA Assay Kit (Invitrogen, Darmstadt, Germany). Sequence data of the
whole BoNT/A8 gene cluster is deposited at GenBank under accession no. KM233166. Please
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note that recently a sequence encoding a highly similar BoNT/A has been deposited indepen-
dently under GenBank accession number KF667385.
Sequence analysis
Genome sequences were assembled using MIRA [91]. The contigs of the genome assembly as
well as Sanger sequences were loaded into the Geneious software package (Biomatters, Auck-
land, New Zealand) and a contig harboring the neurotoxin gene cluster was identified. The
core neurotoxin cluster was elongated by assembling genome sequencing reads over several
rounds until the insertion sites into the chromosome were identified.
Homologous gene sequences were compared to the NCBI database entries using the BLAST
algorithm, and pairwise identities of the aligned sequences were calculated with Geneious ap-
plying the MAFFT algorithm [92].
Toxin extraction
For BoNT/A extraction from culture supernatants of strain Chemnitz monoclonal antibody
(mAb) 4E17.1 was used from the laboratory of James Marks at the University of California,
San Francisco, CA, USA [50,51]. The mAb was immobilized on Protein G Dynabeads as de-
scribed earlier [13]. 20 μL of antibody-coated beads were mixed with a solution of 500 μL of
BoNT/A culture supernatant and 50 μL of 10× phosphate buffered saline (PBS) with 0.01%
Tween (PBS-T) buffer. The mix was incubated for 1 h at room temperature under constant agi-
tation and washed twice with 1 mL of HEPES buffered saline with EDTA and Tween 20 (HBS-
EP, Teknova, Hollister, CA) and once in 100 μL of water.
Antibodies and indirect ELISA
For binding of recombinantly expressed single chain BoNT/A1 and BoNT/A8 against a panel
of in-house generated monoclonal and polyclonal antibodies ([47–49] and unpublished data),
the following antibodies were used: mAb A1688/2, mAb A507/22 and mAb A1437/18 generat-
ed by immunization with BoNT/A1 toxoid and native BoNT/A1 [48]; mAb A709/2 generated
by peptide immunization (aa 72–95; YYDSTYLSTDNEKDNYLKGVTKLF); mAb HcA16/6,
mAb HcA23/26, mAb HcA78/6 and mAb HcA86/2 generated by immunization with recombi-
nant HCA1 fragment [49]; mAb A120/7, mAb A324/10 and mAb A401/3 generated by DNA
immunization [93] followed by boost with BoNT/A1 toxoid; mAb A5/4, mAb A42/2 and mAb
A107/3 generated by immunization with recombinant HCA1 fragment and boost with BoNT/
A1 toxoid. Polyclonal antibodies AR47, AC29 have been described before [47,48].
Native BoNT/A1 (Metabiologics Inc. Madison, WI) or recombinant single chain BoNT/A1
or A8 (500 ng/mL) were coated in PBS containing 3 μg/ml of BSA overnight onto 96-well mi-
crotiter plates (Nunc MaxiSorp, Thermo Scientific, Germany). Unspecific binding was blocked
with casein buffer (Senova, Weimar, Germany) for 1 h at room temperature. After washing,
toxins were incubated for 2 h at room temperature with anti-BoNT/A1-specific monoclonal
and polyclonal antibodies at 10 μg/mL in blocking buffer. The ELISA was developed by incuba-
tion (1 h) with biotin-labeled anti-species secondary antibodies (Dianova, Hamburg, Germany)
diluted in blocking buffer and detection with Streptavidin-PolyHRP40 conjugate (0.5 ng/ml,
Senova) and tetramethylbenzidine (SeramunBlau slow, Seramun, Heidesee, Germany).
Protein sequencing
Toxin was extracted from culture supernatants as above. Beads were reconstituted in 15 μL of
0.5× Tris-PBS buffer (0.5× PBS, 10 mM tris(hydroxymethyl)aminomethane (Tris), pH 7.4),
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and toxins on the beads were digested with 1 μL of 0.1 μg/μL AspN enzyme for 5 min at 52°C.
Following digestion, the supernatant was removed from the beads and supplemented with 2 μL
of 10% trifluoroacetic acid (TFA). The beads were reconstituted in 15 μL of 50 mM ammonium
bicarbonate, pH 7.5 (tryptic buffer), and 2 μL of 0.5 μg/μL trypsin and digested for 5 min at
52°C. Again, the supernatant was removed from the beads and supplemented with 2 μL of 10%
TFA. Finally, the beads were reconstituted again in 15 μL of tryptic buffer and 1 μL of
0.2 μg/μL chymotrypsin and digested for 5 min at 52°C. The supernatant was removed and
supplemented with 2 μL of 10% TFA.
Chromatographic separation of peptides and mass spectrometric analysis by Fourier trans-
form ion cyclotron resonance (FT-ICR)-MS as well as database searches were performed as de-
scribed earlier [13], with the exception that an in-house amino acid substitution database for
BoNT/A1 was used.
Peptides and proteins
Wild-type human SNAP-25 aa 1–206 N-terminally fused to His6tag (hH6SNAP-25) was ob-
tained from ATGen, Sampyeong-dong, South Korea. Recombinant rat SNAP-25 fused to a
C-terminal His6tag (rSNAP-25H6) was expressed as described previously [94]. Recombinant
luminal domain 4 (aa 454–579) of rat SV2C fused to GST (GST-rSV2C 454–579) was express-
ed and isolated as described previously [27]. The genes encoding aa 1–438 (LC) of BoNT/A1
(GenBank ID AAA23262) and BoNT/A8, aa 827–1297 of BoNT/A8 (HCA8) and full-length
BoNT/A8 were amplified by PCR and inserted into a pQE-based expression plasmid (Qiagen,
Hilden, Germany) encoding a C-terminal Streptag yielding pLC-A1S, pLC-A8S, pHCA8S and
pBoNTA8S. The active full-length single chain (sc) BoNT/A1 and scBoNT/A8 were expressed
recombinantly in E. coli in a biosafety level 2 containment (project identifier GAA Hannover
A/Z 40654/3/123). Single-step purification of LC/A1S, LC/A8S, HCA1S, HCA8S, scBoNTA1S
and scBoNTA8S was performed as described previously [25]. scBoNT/A were activated into
the dichain BoNT/A by a C. botulinum culture supernatant extract and subjected to gelfiltra-
tion in 50 mM sodiumphosphate, pH 7.4, 150 mMNaCl. The LC/AX were dialyzed against
toxin assay buffer (150 mM potassium glutamate and 20 mMHEPES-KOH, pH 7.2). HCAX
were kept in 150 mMNaCl, 100 mM Tris-HCl, pH 8.0 and scBoNT/AX in 100 mM Tris-HCl,
pH 8.0. All proteins were flash frozen in liquid nitrogen, and stored at—70°C.
GST pull-down assay
Glutathione-S-transferase (GST) or GST-rSV2C 454–579 fusion protein (150 pmol each) im-
mobilized to 10 μL of glutathione-sepharose-4B matrix was incubated with recombinant HC-
fragment of BoNT/A1 and A8 (100 pmol each), respectively, in a total volume of 200 μL of
20 mM Tris—HCl, 80 mM NaCl, pH 7.4, supplemented with 0.5% Triton X-100 (Tris/NaCl/
Triton) buffer for 2 h at 4°C. Beads were collected by centrifugation and washed twice with
200 μL of Tris/NaCl/Triton buffer. Beads were incubated for 20 min at 37°C in SDS sample
buffer, analyzed by 12.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), detected by
Coomassie blue staining, densitometrically quantified as binding in mol% of GST-rSV2C and
set in ratio to HCA1 binding.
Binding of HC-fragments to synaptosomes
Rat brain synaptosomes were freshly prepared and HC-fragment of BoNT/A1 (
35S-HCA1) was
radiolabeled by in vitro transcription/translation as previously described [25]. 35S-HCA1 was
bound in the presence of increasing concentrations of recombinant HCA1S and HCA8S
(0.003–3.5 μM) to synaptosomes in a total volume of 100 μL of physiological buffer (140 mM
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NaCl, 5 mM KCl, 1 mMMgCl2, 1 mM CaCl2, 20 mMHEPES, 10 mM glucose, 0.5% BSA,
pH 7.4) with the final synaptosomal protein adjusted to a concentration of 10 mg/ml for 2 h at
4°C. Controls were performed with samples lacking synaptosomes and/or recombinant HCA.
After incubation, synaptosomes were collected by centrifugation (5,000 × g; 5 min) and un-
bound material in the supernatant fraction was discarded. The pellet fractions were washed two
times each with 100 μL of physiological buffer and incubated for 20 min at 37°C in SDS sample
buffer and subsequently subjected to SDS-PAGE and autoradiography. Bound 35S-HCA1 was
quantified with the Advanced Image Data Analyzer (AIDA 2.11) software (Raytest, Strauben-
hardt, Germany) and calculated after subtraction of the value obtained for control sample in the
absence of synaptosomes as the percentage of the total 35S-HCA1 in the assay. The inflection
points of the binding curves were determined by fitting the data to the sigmoidal dose—
response equation with variable slope, bottom constraint>0, top constraint<100 using Prism
4.03 (GraphPad Software, La Jolla, CA, USA) and expressed as EC50 values in units of μM.
Mass spectrometric Endopeptidase activity assay (Endopep-MS)
The Endopep-MS reaction was performed as described previously [50] with a few modifica-
tions. After immunoextraction of the toxin from culture supernatants as described the beads
were incubated with the 4 nmol peptide substrate (Biotin-KGSNRTRIDQGNQRATRXLGGK-
Biotin where X represents norleucine) for 40 min in 40 μL of reaction buffer (20 mMHEPES
pH 7.3, 10 mM dithiothreitol, 20 μMZnCl2, 1 mg/mL BSA). 18 μL of the sample was combined
with 2 μL of 1% formic acid and 2 μL of a 100 μM internal standard peptide (RA(+7)
TRXLGGK-Biotin) for SNAP-25 peptide quantification. LC-MS/MS analysis of the cleavage
products was performed as described by Parks et al. [95]. Additionally, the antibody-coated
beads which were used for BoNT extraction were washed twice with 100 μL of water and recon-
stituted in 20 μL of tryptic buffer and 2 μL of 0.5 μg/μL trypsin and digested for 5 min at 52°C.
After incubation 20 μL of each sample was combined with 2 μL of 1% formic acid and 2 μL of a
1 μM internal standard peptide for BoNT quantification (L(+7)VASNWYNR). LC-MS/MS
analysis of the BoNT peptide fragment was performed on an AB Sciex 5500 triple quadrupole
mass spectrometer (AB Sciex, Foster City, CA, USA).
For the Endopep-MS with human His-tagged full-length SNAP-25 (hH6SNAP-25) protein
1 nM recombinant light chains LC/A1S and LC/A8S were incubated in 20 μL of reaction buffer
(20 mMHEPES (pH 7.3), 10 mM dithiothreitol, 20 μMZnCl2 and 1 mg/mL BSA) with 4 μM
hH6SNAP-25 protein. The samples were incubated at 37°C for 30 min and then inactivated at
95°C for 10 min in a PCR cycler. Afterwards 2 μL of 1% formic acid and 2 μL of 100 μM inter-
nal standard (RATKML(+7)GSG) were added for SNAP-25 protein quantification. LC-MS/MS
analysis was performed on an EASY nanoLC coupled to a linear ion trap (LTQ) Orbitrap Dis-
covery (both Thermo Scientific, Bremen, Germany).
Time-dependent SNAP-25 endopeptidase assay
In time-dependent SNAP-25 endopeptidase assays, 3 μM rSNAP-25H6 was incubated in the
presence of 0.5 nM LC/A in a total volume of 120 μL in toxin assay buffer at 37°C. Aliquots
(15 μL) were withdrawn at specified time intervals. Reactions were stopped by mixing with 5 μL
of 4-fold Laemmli buffer. Samples were boiled for 2 min and subjected to 15% SDS-PAGE. Pro-
teins were visualized by staining with Coomassie blue and quantified by densitometry.
Mouse phrenic nerve (MPN) hemidiaphragm assay
The MPN assay was performed as described previously [74]. In short, the phrenic nerve was
continuously stimulated at 5–25 mA with a frequency of 1 Hz and with 0.1 ms pulse duration.
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Isometric contractions were transformed using a force transducer and recorded with VitroDat
Online software (FMI GmbH, Seeheim, Germany). The time required to decrease the ampli-
tude to 50% of the starting value (paralytic half-time) was determined. To compare the altered
neurotoxicity of BoNT/A8 with BoNT/A1 three point concentration—response curves deter-
mined minimum in triplicates were compiled to which the following power functions could
be ascribed: y(BoNT/A1S; 0.3, 1, 3 pM) = 73.368x–0.2941, R2 = 0.9999 and y(BoNT/A8S; 1, 3,
10 pM) = 122.83x–0.2867, R2 = 0.9637. To yield an identical paralytic half-time of 75 min, 6.0-
fold higher concentrations of BoNT/A8 were required.
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